194861-70-6

Usage

Uses

Used in Pharmaceutical Industry:
Ginsenoside Rs3 is used as a therapeutic agent for its potential anti-inflammatory, antioxidant, and immune-modulating properties. It is being studied for its potential in treating conditions such as diabetes, cardiovascular disease, and cancer.
Used in Nutraceutical Industry:
Ginsenoside Rs3 is used as a dietary supplement for its potential health benefits, including improving cognitive function, reducing stress, and enhancing physical endurance.
Used in Cosmetic Industry:
Ginsenoside Rs3 is used as an ingredient in skincare products for its potential anti-aging and skin health benefits due to its antioxidant properties.
Used in Functional Food Industry:
Ginsenoside Rs3 is used as an ingredient in functional foods and beverages for its potential health benefits and to enhance overall well-being.

InChI:InChI=1/C44H74O14/c1-22(2)11-10-15-43(8,53)25-12-16-41(6)24-13-18-44(9)40(4,5)30(14-17-42(44,7)26(24)19-27(47)31(25)41)57-39-37(35(51)32(48)28(20-45)55-39)58-38-36(52)34(50)33(49)29(56-38)21-54-23(3)46/h11,24-39,45,47-53H,10,12-21H2,1-9H3/t24?,25?,26?,27-,28+,29+,30?,31?,32+,33+,34-,35-,36+,37+,38-,39-,41+,42+,43-,44-/m0/s1

Upstream product

• 108-05-4 vinyl acetate 
• 38243-03-7 20(R)-ginsenoside Rg₃ 
• 14197-60-5 ginsenoside Rg₃ 
• 41753-43-9 Ginsenoside Rb₁ 
• 126252-51-5 (3β,12β,20R/20S)-12,20-dihydroxydammar-24-en-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside 

Relevant academic research and scientific papers

Regioselective acylation of ginsenosides by Novozyme 435 to generate molecular diversity

Ginsenosides are major bioactive constituents of ginseng (Panax spp.; Araliaceae), a traditional Chinese medicinal herb. In order to increase the molecular diversity and broaden the potential usage of ginsenosides, ginsenosides Rd (1), Rg3 (2), (20R)-Rg3 (3), Rh2 (4), Re (5), Rh1 (8), Rg2 (9), gypenoside XVII (6), and pseudoginsenoside F11 (7) were regioselectively acylated with vinyl acetate, catalyzed by Novozyme 435 (lipase B from Candida antarctica), in organic solvents to afford different mono-acetyl ginsenosides. Ginsenoside Rd (1) was also acylated with vinyl decanoate or vinyl cinnamate to generate 1b and 1c, respectively. Acylation of glucosylated ginsenosides (1-4, 6, 8) occurred at the primary 6-OH function of the terminal glucose (Glc) moiety of the sugar at C(3) or C(20) of the dammarane-type aglycone. In contrast, ginsenosides 5, 7, and 9, containing mixed sugar moieties, resulted in acylation of both the rhamnose (Rha) and the glucose (Glc) moieties. In the case of ginsenoside Re (5) and pseudoginsenoside F11 (7), acylation at the secondary 4-OH function of the terminal Rha moiety, attached at C(3) of the aglycone, is preferred. The structures of all acylated products were determined by extensive MALDI-TOF-MS and NMR analyses.

Biocatalytic generation of molecular diversity: Modification of ginsenoside Rb1 by β-1,4-Galactosyltransferase and Candida antarctica lipase

A series of specific derivatives of the complex protopanaxadiol glycoside ginsenoside Rb1 (1) were prepared by catalysis of two unrelated enzymes: the β-1,4-galactosyltransferase from bovine colostrum (GalT) and the lipase B from Candida antarctica (Novozym 435). Both of the enzymes showed the expected regioselectivity towards specific glucose OH groups (i.e., OH-C(4) for GalT and preferentially the primary OH-C(6) for Novozym 435), accompanied by a nonpredictable 'site selectivity' for the gentiobiose disaccharide unit linked at C(20) of the dammarane skeleton. The galactosylated products 1a-e and the acetylated products 1f-h were isolated by HPLC and fully characterized by extensive MS and NMR analysis.